Insys Therapeutics (INSY) Downgraded by ValuEngine to “Strong Sell”
ValuEngine lowered shares of Insys Therapeutics (NASDAQ:INSY) from a sell rating to a strong sell rating in a research report released on Thursday.
INSY has been the topic of several other research reports. Jefferies Group decreased their price target on Insys Therapeutics from $14.00 to $11.00 and set a buy rating on the stock in a research note on Friday, November 3rd. Oppenheimer reissued a hold rating on shares of Insys Therapeutics in a research note on Sunday, November 12th. Finally, Zacks Investment Research lowered Insys Therapeutics from a hold rating to a sell rating in a research note on Saturday, February 3rd. Three analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and an average target price of $9.38.
Shares of Insys Therapeutics (NASDAQ INSY) traded up $0.46 on Thursday, reaching $7.77. The company’s stock had a trading volume of 722,374 shares, compared to its average volume of 573,212. Insys Therapeutics has a 12 month low of $4.10 and a 12 month high of $15.02. The stock has a market cap of $569.67, a price-to-earnings ratio of -3.05 and a beta of 1.02.
COPYRIGHT VIOLATION WARNING: This article was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.dailypolitical.com/2018/03/04/insys-therapeutics-insy-downgraded-by-valuengine-to-strong-sell.html.
About Insys Therapeutics
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.